February 12th 2025
Demonstrating clinical benefit is the ultimate gateway to smoother patient access.
Adoption of Digital Technologies in Clinical Trials
March 3rd 2021Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.
New Horizons for Patient-Centric Drug Delivery
November 20th 2020Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.
Tapping Microbiome Science for New Treatments and Answers to Drug Efficacy
October 26th 2020Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to understand the subtleties of how drugs interact with different human ‘host’ environments, unlocking new potential for stratified treatments.
COVID-19 Vaccine Concerns Prompt Clinical Trial Transparency
September 20th 2020With all eyes on efforts to research and test potential vaccines and therapies to combat the coronavirus pandemic, fears about overly accelerated development programs has heightened demands for wider access to information on study protocols, statistical analysis plans, and early results.
Global Regulatory Collaborations Aim to Speed Access to New Vaccines & Drugs
June 29th 2020The need for treatments to combat the spread of COVID-19 is promoting greater cooperation among drug regulatory authorities around the world, with FDA officials communicating more frequently with their counterparts in Europe, Canada, Japan and other nations through established programs and agreements.
Vaccine Production Key to Global Pandemic Response
May 17th 2020Biopharma companies have been working overtime to supply billions of doses of any safe and effective preventive. But the tight timeframe means they can't wait for final clinical test results to begin preparing large-scale manufacturing operations and to address critical supply chain issues.
Drug Development in Wartime: Driving Tomorrow's R&D Decisions with Today's COVID-19 Data
May 10th 2020The only way for pharma companies to know where to focus their COVID-19 R&D efforts is for the industry to have access to real-time, real-world evidence of what’s working to keep people alive, write Travis Leonardi and William Kirsh.